<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641264</url>
  </required_header>
  <id_info>
    <org_study_id>294</org_study_id>
    <nct_id>NCT00641264</nct_id>
  </id_info>
  <brief_title>Quality of Life Validation in Laryngitis</brief_title>
  <official_title>Laryngopharyngeal Reflux Health Related Quality of Life (LPR-HRQL) Questionnaire Development and Psychometric Testing in Patients Receiving Omeprazole 20 mg Bid as Treatment for Laryngopharyngeal Reflux.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to establish the psychometric properties of a new
      disease specific Quality of Life questionnaire, the LPR-HRQL. The specific properties of the
      questionnaire that were evaluated were: validity, reliability, and responsiveness to change
      (as a measure of treatment effect).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LPR-HRQL questionnaire, which measured symptom distress and the effects of LPR on voice, cough, throat clearing, swallow , and overall impact of acid reflux</measure>
    <time_frame>2 monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments via adverse event recording and physical examinations</measure>
    <time_frame>2 monthly</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Laryngopharyngeal Reflux (LPR)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <other_name>Losec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life questionnaire</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New Laryngopharyngeal reflux diagnosis less than 1 month or relapsed patients not
             under current treatment

        Exclusion Criteria:

          -  Unable to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Fernstrom</last_name>
    <role>Study Director</role>
    <affiliation>Nexium Global Product Director, AstraZeneca</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>June 10, 2009</last_update_submitted>
  <last_update_submitted_qc>June 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind, MD - Nexium Medical Science Director</name_title>
    <organization>Astra Zeneca</organization>
  </responsible_party>
  <keyword>Laryngopharyngeal reflux (LPR)</keyword>
  <keyword>Omeprazole</keyword>
  <keyword>Losec</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Laryngitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
    <mesh_term>Laryngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

